HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SOMERVILLE, B. W. Search for Related Content PubMed PubMed Citation Articles by SOMERVILLE, B. W.

Estrogen-withdrawal migraine

I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration

Division of Neurology, School of Medicine, and the School of Obstetrics and Gynaecology, University of New South Wales, Australia.

The minimum exposure to estrogen required to cause estrogen-withdrawal migraine has been studied by giving long-acting estradiol valerate to four women and short-acting estradiol benzoate to two women. It was found that several days of exposure to high estrogen levels were needed to cause migraine on estrogen withdrawal. Oral administration of estrogen supplements in the form of estradiol valerate or as conjugated equine estrogens during the premenstrual phase in four women did not significantly affect plasma levels of estradiol, nor was it effective in preventing menstrual migraine.

Received for publication August 22, 1974.

Reprint requests should be addressed to Dr. Somerville, Honorary Associate Physician, Prince Henry Hospital, Little Bay, N.S.W. 2036, Australia.

This article has been cited by other articles:

				E. A. MacGregor, A. Frith, J. Ellis, L. Aspinall, and A. Hackshaw Prevention of menstrual attacks of migraine: A double-blind placebo-controlled crossover study Neurology, December 26, 2006; 67(12): 2159 - 2163. [Abstract] [Full Text] [PDF]

				E. A. MacGregor, A. Frith, J. Ellis, L. Aspinall, and A. Hackshaw Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen Neurology, December 26, 2006; 67(12): 2154 - 2158. [Abstract] [Full Text] [PDF]

				J. L. Brandes The influence of estrogen on migraine: a systematic review. JAMA, April 19, 2006; 295(15): 1824 - 1830. [Abstract] [Full Text] [PDF]

				R.E. Nappi, G. Sances, B. Brundu, S. De taddei, A. Sommacal, N. Ghiotto, F. Polatti, and G. Nappi Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval Hum. Reprod., December 1, 2005; 20(12): 3423 - 3428. [Abstract] [Full Text] [PDF]

				M.-G. Bousser Estrogens, Migraine, and Stroke Stroke, November 1, 2004; 35(11_suppl_1): 2652 - 2656. [Abstract] [Full Text] [PDF]

				S. D. Silberstein, A. H. Elkind, C. Schreiber, and C. Keywood A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine Neurology, July 27, 2004; 63(2): 261 - 269. [Abstract] [Full Text] [PDF]

				A. M. Case and R. L. Reid Effects of the Menstrual Cycle on Medical Disorders Arch Intern Med, July 13, 1998; 158(13): 1405 - 1412. [Abstract] [Full Text]

				K.M.A. Welch Drug Therapy of Migraine N. Engl. J. Med., November 11, 1993; 329(20): 1476 - 1483. [Full Text]